What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Visual acuity
- Surgery
Ophthalmology, Visual acuity, Surgery, Macular degeneration and Fluorescein angiography are his primary areas of study.
His Ophthalmology study combines topics from a wide range of disciplines, such as Diabetic retinopathy, Prospective cohort study and Implant.
His Visual acuity research integrates issues from Pro re nata, Optometry, Randomized controlled trial and Aflibercept.
Glenn J. Jaffe combines subjects such as Internal medicine and Uveitis with his study of Surgery.
The Macular degeneration study combines topics in areas such as Ranibizumab, Fundus, Atrophy and Confidence interval.
The study incorporates disciplines such as Fundus photography and Glaucoma in addition to Fluorescein angiography.
His most cited work include:
- Ranibizumab and bevacizumab for neovascular age-related macular degeneration. (1886 citations)
- Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. (1180 citations)
- Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel (703 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Ophthalmology, Visual acuity, Surgery, Macular degeneration and Retinal.
His Ophthalmology and Fluorescein angiography, Uveitis, Macular edema, Optical coherence tomography and Fluocinolone acetonide investigations all form part of his Ophthalmology research activities.
His Fluocinolone acetonide study integrates concerns from other disciplines, such as Implant and Posterior segment of eyeball.
His work in Visual acuity addresses issues such as Randomized controlled trial, which are connected to fields such as Clinical trial.
His Surgery study frequently links to other fields, such as Retinopathy.
His Macular degeneration research is multidisciplinary, incorporating elements of Lesion, Age related and Atrophy.
He most often published in these fields:
- Ophthalmology (53.78%)
- Visual acuity (25.70%)
- Surgery (22.25%)
What were the highlights of his more recent work (between 2017-2021)?
- Ophthalmology (53.78%)
- Visual acuity (25.70%)
- Macular degeneration (19.87%)
In recent papers he was focusing on the following fields of study:
Glenn J. Jaffe spends much of his time researching Ophthalmology, Visual acuity, Macular degeneration, Optical coherence tomography and Retinal.
His studies link Prospective cohort study with Ophthalmology.
His Visual acuity study incorporates themes from Hazard ratio, Randomized controlled trial, Uveitis and Ranibizumab.
He has included themes like Aflibercept and Confidence interval in his Randomized controlled trial study.
His Macular degeneration study also includes
- Atrophy and related Lesion,
- Retinal pigment epithelium that connect with fields like Disease.
His Fluocinolone acetonide study integrates concerns from other disciplines, such as Surgery, Implant and Posterior segment of eyeball.
Between 2017 and 2021, his most popular works were:
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration (147 citations)
- Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group (68 citations)
- Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III (58 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Visual acuity
- Cancer
Glenn J. Jaffe focuses on Macular degeneration, Ophthalmology, Visual acuity, Prospective cohort study and Atrophy.
His Macular degeneration research incorporates themes from Clinical trial, Incidence, Age related and Cohort.
His research ties Occlusion and Ophthalmology together.
His research integrates issues of Randomized controlled trial and Ranibizumab in his study of Visual acuity.
His Randomized controlled trial research includes elements of Adverse effect, Aflibercept and Uveitis.
His Prospective cohort study research is multidisciplinary, incorporating perspectives in Macula Lutea and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
